ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Genprex Inc

Genprex Inc (GNPX)

0.4196
0.0376
( 9.84% )
Updated: 14:06:58

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.4196
Bid
0.41
Ask
0.4197
Volume
1,056,103
0.39 Day's Range 0.43
0.2806 52 Week Range 16.94
Market Cap
Previous Close
0.382
Open
0.4034
Last Trade
199
@
0.4196
Last Trade Time
14:06:58
Financial Volume
$ 434,673
VWAP
0.411582
Average Volume (3m)
459,285
Shares Outstanding
2,588,546
Dividend Yield
-
PE Ratio
-0.04
Earnings Per Share (EPS)
-11.92
Revenue
-
Net Profit
-30.86M

About Genprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who cur... Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Genprex Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNPX. The last closing price for Genprex was $0.38. Over the last year, Genprex shares have traded in a share price range of $ 0.2806 to $ 16.94.

Genprex currently has 2,588,546 shares outstanding. The market capitalization of Genprex is $988,824.57 . Genprex has a price to earnings ratio (PE ratio) of -0.04.

GNPX Latest News

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes PR Newswire AUSTIN, Texas, Sept. 23, 2024 Company's CEO and CFO Highlights its Cutting-Edge Gene...

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Formation of Mesothelioma Clinical Advisory Board PR Newswire AUSTIN, Texas, Sept. 19, 2024 Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics PR...

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes PR Newswire AUSTIN, Texas, Sept. 4, 2024 Intends to Create Two...

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences PR Newswire AUSTIN, Texas, Sept. 3, 2024 Presentation to Highlight the Company's Gene Therapies for...

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials PR Newswire AUSTIN, Texas, Aug. 15, 2024 Chief Medical Officer...

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer PR Newswire AUSTIN, Texas, Aug. 14, 2024 Demonstrates Prolonged Progression...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01964.90.40.430.28064156210.37013389CS
4-0.2909-40.94299788880.71050.80.28068939780.47270378CS
12-1.5704-78.91457286431.992.130.28064592850.60403406CS
26-2.7504-86.76340694013.174.08990.28062695761.06780063CS
52-14.7804-97.239473684215.216.940.28063220556.02614899CS
156-113.9804-99.6332167832114.4144.80.280683272289.86134761CS
260-34.3804-98.794252873634.8308.80.28061299778115.55061108CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 1.3901
(140.09%)
166.83M
RSLSReShape Lifesciences Inc
$ 11.19
(72.26%)
4.69M
TGLTreasure Global Inc
$ 1.11
(63.16%)
132.32M
LASELaser Photonics Corporation
$ 16.005
(53.75%)
9.76M
UXINUxin Ltd
$ 2.36
(48.90%)
15.59M
ELABElevai Labs Inc
$ 0.11
(-60.71%)
15.51M
ADTXAditxt Inc
$ 0.27
(-29.43%)
2.4M
FRGTFreight Technologies Inc
$ 0.0806
(-29.17%)
23.08M
ZJYLJin Medical International Ltd
$ 2.92
(-28.43%)
785.88k
ANEBAnebulo Pharmaceuticals Inc
$ 2.22
(-27.92%)
100.73k
XPONExpion360 Inc
$ 0.1054
(24.29%)
382.08M
KAVLKaival Brands Innovations Group Inc
$ 1.3901
(140.09%)
166.83M
NVDANVIDIA Corporation
$ 115.76
(-0.21%)
140.83M
INTCIntel Corporation
$ 22.7701
(4.26%)
135.46M
TGLTreasure Global Inc
$ 1.11
(63.16%)
132.32M

GNPX Discussion

View Posts
georgie18 georgie18 4 hours ago
GNPX...40s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 3904

Friday, September 20, 2024 1:58:52 PM

Post#
3906
of 3907
GNPX...40s starting here...🥳

georgie18

Member Level
Re: georgie18 post# 383666

Thursday, September 19, 2024 10:53:00 AM

Post#
383681
of 383718
GNPX...389...🥳

georgie18

Member Level
Re: None

Thursday, September 19, 2024 9:02:50 AM

Post#
3902
of 3903
GNPX...37... https://schrts.co/QAZnUXyU ...🥳...Reversal Candle off the bottom...2.5 million Float...Scaling in here...
👍️0
laraz5 laraz5 2 days ago
New O/S 2,588,546 what's a half million between friends?


Wheres the money?


This is only the beginning?

Jail?

SEC where you at?

IMO
👍️0
georgie18 georgie18 3 days ago
GNPX...40s starting here...🥳

georgie18

Member Level
Re: georgie18 post# 383666

Thursday, September 19, 2024 10:53:00 AM

Post#
383681
of 383718
GNPX...389...🥳

georgie18

Member Level
Re: None

Thursday, September 19, 2024 9:02:50 AM

Post#
3902
of 3903
GNPX...37... https://schrts.co/QAZnUXyU ...🥳...Reversal Candle off the bottom...2.5 million Float...Scaling in here...
👍️0
laraz5 laraz5 4 days ago
Oh look useless dilution charts and posts about nothing?

Onward to the increased O/S?

New lows?

Whos asking where the money is going?

IMO
👍️0
georgie18 georgie18 4 days ago
GNPX...389...🥳

georgie18

Member Level
Re: None

Thursday, September 19, 2024 9:02:50 AM

Post#
3902
of 3903
GNPX...37... https://schrts.co/QAZnUXyU ...🥳...Reversal Candle off the bottom...2.5 million Float...Scaling in here...
👍️0
jedijazz jedijazz 4 days ago
NEWS: Genprex (NASDAQ: GNPX) Announces Formation of Mesothelioma Clinical Advisory Board
PR Newswire
Thu, September 19, 2024 at 9:29 AM EDT
In This Article:
GNPX
+1.92%

Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma

AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-renown researchers from major research institutions specializing in the treatment of mesothelioma.


"We continue to develop a robust research program around our Reqorsa® Gene Therapy to expand its potential benefit to new patient populations, and we are pleased to assemble a group of highly respected physicians to assist in advancing our preclinical program in mesothelioma," said Ryan Confer, President and Chief Executive Officer at Genprex. "This group of world class researchers will not only provide advice and input to assist the Genprex team in moving forward our potentially promising program in mesothelioma, but the formation of this board underscores our continuous efforts to advance our research programs in some of the most difficult to treat cancers with patients who have limited treatment options or an unmet medical need."

Expression of TUSC2 is downregulated in 84% of mesotheliomas. Genprex collaborators at New York University Langone Health will present additional positive preclinical data on TUSC2 for the treatment of mesothelioma next month at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. TUSC2 is the tumor suppressor gene used in Reqorsa® Gene Therapy (Quaratusugene ozeplasmid). REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.

According to the Center for Disease Control, mesothelioma is a cancer that forms in the thin tissue that lines many internal organs, called the mesothelium. The most common kind of mesothelioma forms in the tissue around the lungs, called the pleura. This is called pleural mesothelioma, which accounts for 80-90% of all mesothelioma diagnoses. Approximately 3,000 new cases of mesothelioma are diagnosed each year in the U.S., and there are approximately 2,500 mesothelioma-related deaths each year in the U.S. The life expectancy for pleural mesothelioma is 18 months, and the 3-year survival rate with treatment for pleural mesothelioma is 23%.

About Reqorsa® Gene Therapy
REQORSA (quaratusugene ozeplasmid) for NSCLC and small-cell lung cancer (SCLC) consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (Genprex's ONCOPREX® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells.

Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment in mesothelioma; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com
https://genprex.com/news/genprex-announces-formation-of-mesothelioma-clinical-advisory-board/
@Genprex
👍️0
georgie18 georgie18 4 days ago
GNPX...37... https://schrts.co/QAZnUXyU ...🥳...Reversal Candle off the bottom...2.5 million Float...Scaling in here...
👍️0
Monksdream Monksdream 5 days ago
GNPX new 52 week low
👍️0
jedijazz jedijazz 5 days ago
$GNPX (Nasdaq) Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes: https://genprex.com/news/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-therapy-to-treat-type-1-and-type-2-diabetes/ #GNPX #FDAinPLAY
👍️0
jedijazz jedijazz 1 week ago
$GNPX @Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: https://genprex.com/news/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/ #FDA
👍️ 1 💯 1
Monksdream Monksdream 2 weeks ago
GNPX new 52 week low
👍️0
laraz5 laraz5 2 weeks ago
***scam diluting machine****

The O/S is blowing up?


IMO
👍️0
jedijazz jedijazz 2 weeks ago
$GNPX @Nasdaq @Genprex Latest Press Releases https://nasdaq.com/market-activity/stocks/gnpx/press-releases #Nasdaq #News
👍️ 1 💯 1
glenn1919 glenn1919 2 weeks ago
GNPX.......................https://stockcharts.com/h-sc/ui?s=GNPX&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 2 weeks ago
What leaked?
👍️0
jedijazz jedijazz 2 weeks ago
$GNPX (Nasdaq) Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials; Chief Medical Officer, Mark Berger, MD https://www.genprex.com/videos/chief-medical-officer-mark-berger-md-discusses-positive-patient-outcomes-in-two-lung-cancer-clinical-trials/
👍️ 1 💯 1
jedijazz jedijazz 2 weeks ago
$GNPX Excellent News! Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma #Bulish #nasdaq

https://www.stocktitan.net/news/GNPX/genprex-collaborators-to-present-positive-preclinical-data-on-the-s8nfyo6tcvqp.html
👍️ 1 💯 1
ProfitScout ProfitScout 2 weeks ago
$GNPX News: Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma

AUSTIN, Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.

"We are very pleased that these studies with our academic partners have been selected for presentation, which expands the growing body of preclinical evidence supporting REQORSA's potential to treat a variety of cancers," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to these presentations next month which will share the compelling data that support the potential for new clinical studies evaluating Reqorsa as a potential treatment for additional types of lung cancer, mesothelioma and glioblastoma."

Featured Genprex-supported posters to be presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:

Title: "TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib"
Collaborator: The University of Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372

Title: "TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells"
Collaborator: New York University Langone Health
Catalog Number: 364
Presentation Number: PB352

Title: "Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas Health Science Center at Houston
Catalog Number: 130
Presentation Number: PB118

Genprex has filed two provisional patent applications based on data from two of the presentations. One application involves using REQORSA to treat mesothelioma and the other to treating glioblastoma. Genprex is a co-owner of the applications along with the respective institutions. TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

https://c212.net/c/img/favicon.png?sn=DA00335&sd=2024-09-09 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302241636.html

SOURCE Genprex, Inc.
👍️ 1
ProfitScout ProfitScout 3 weeks ago
$GNPX News: Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program

New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes

AUSTIN, Texas, Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D).

"Genprex's diabetes program has received the attention of several potential investors, partners, collaborators and pharmaceutical companies, and we believe separating it from our oncology programs could help increase interest, expedite clinical development and unlock the value of our novel diabetes program," said Ryan Confer, President and Chief Executive Officer at Genprex. "The new subsidiary would be positioned to be a pure-play diabetes-focused biopharmaceutical company, while Genprex would be a pure-play oncology-focused biopharmaceutical company. This contemplated separation of entities could enable potential direct investment and strategic collaboration into the advancement of the diabetes program. Diabetic patients are in need of advanced therapies, and we believe GPX-002 holds the potential for disease modification for long-term effectiveness, which could directly impact the global diabetes epidemic."

The planned spin-out transaction would allow both Genprex and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The spin-out, if completed as presently contemplated, would result in NewCo focusing on developing GPX-002, while Genprex would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates Genprex's strong ongoing commitment to the Company's streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024, subject to adequate financing, the satisfaction of customary conditions and final approval from the Genprex management and Board of Directors.

The Company's goal for separating the diabetes clinical development program from its oncology program follows closely behind Genprex's recent announcement to re-focus its oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, the Company continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, the Company is considering various strategic alternatives and opportunities to enhance stockholder value.

GPX-002, which has been exclusively licensed from the University of Pittsburgh, is being developed using the same construct for the treatment of both T1D and T2D. The same general novel approach is used in each of T1D and T2D whereby an adeno-associated virus (AAV) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. The diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh.

"With the potential to address the entire diabetes market, we believe our gene therapy approach would position NewCo as an innovator in emerging diabetes therapies," continued Confer. "The most significant advancement in the treatment of diabetes happened more than 100 years ago when insulin was first introduced to treat T1D patients. We believe our treatment has the potential to disrupt the diabetes market by replacing the daily burden of blood glucose monitoring and insulin replacement therapy, as well as the need for GLP-1 treatments in T2D."

About GPX-002 and Diabetes

In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In vivo, preclinical studies show that GPX-002 restored normal blood glucose levels for an extended period of time.

In February 2023, research collaborators at the University of Pittsburgh presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Germany.

The statistically significant study results showed the treated animals had:

Decreased insulin requirements
Increased c-peptide levels
Improved glucose tolerance compared to baseline
In April 2023, Genprex hosted a Key Opinion Leader virtual event entitled "Novel Gene Therapy to Treat Type 1 Diabetes," which discussed preclinical data reported at ATTD 2023 supporting gene therapy to treat T1D. Watch the KOL event here.

In a similar approach for T2D, GPX-002 (formerly known as GPX-003), where autoimmunity is not at play, is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

According to the U.S. Center for Disease Control as of 2024, 38.4 million Americans, or approximately 11.6% of the U.S. population, have diabetes. It is also believed that more than 97 million Americans aged 18 years or older have prediabetes. In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million in 2045. Also in 2021, diabetes caused more than 6.7 million deaths globally and diabetes resulted in approximately $966 billion dollars in health expenditures, a 316% increase over the preceding fifteen years.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the potential separation of its diabetes clinical development program, including the anticipated benefits of the internal reorganization, the expected timing of the reorganization and/or if it is completed as contemplated or at all; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its short-term and long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com


https://c212.net/c/img/favicon.png?sn=DA97213&sd=2024-09-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-therapy-to-treat-type-1-and-type-2-diabetes-302237871.html

SOURCE Genprex, Inc.
👍️ 1
jedijazz jedijazz 3 weeks ago
$GNPX NEWS! @Genprex to Present and Participate at Upcoming September Investor and Industry Conferences; Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes https://finance.yahoo.com/news/genprex-present-participate-upcoming-september-121500840.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance #BreakingNews
👍️ 2 💥 1 💯 1
jedijazz jedijazz 3 weeks ago
Good morning. Pre-market news out for Genprex!
👍️0
jedijazz jedijazz 4 weeks ago
$GNPX on Nasdaq.com https://www.nasdaq.com/market-activity/stocks/gnpx
👍️ 1 💯 1
laraz5 laraz5 4 weeks ago
What a load of shit? No one is looking at pyramid schemes low level fund stealing shells anywhere on Google or any other search engine?


IMO
👍️0
jedijazz jedijazz 4 weeks ago
$GNPX Genprex (GNPX) in the biotech sector is seeing a substantial increase in search activity, as determined by #InvestChannel and TipRanks

Genprex (GNPX) had a 1,669% surge in interest; Genprex, Inc. is a clinical-stage gene therapy company

https://www.tipranks.com/news/the-fly/biotech-alert-searches-spiking-for-these-stocks-today-301?mod=mw_quote_news#google_vignette Nasdaq
👍️ 1 💥 1 💯 1
ProfitScout ProfitScout 4 weeks ago
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes

Video Highlights Recent Oncology Clinical Development Program Updates

AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.

The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.

The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."

Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."

On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.

We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."

To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html

SOURCE Genprex, Inc.
👍️ 1
jedijazz jedijazz 1 month ago
$GNPX +6.82% -CMO Mark Berger Provides Overview of Recent Positive Clinical Patient Outcomes;
Video Highlights Recent Oncology Clinical Development
@Genprex Releases New Video Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
https://www.genprex.com/videos/chief-medical-officer-mark-berger-md-discusses-positive-patient-outcomes-in-two-lung-cancer-clinical-trials/ $JNJ
👍️0
Monroe1 Monroe1 1 month ago
Took a $20 starter to watch this ... who knows. On radar.
👍️0
Monksdream Monksdream 1 month ago
Nope
👍️0
Monroe1 Monroe1 1 month ago
is now the time to buy?
👍️0
Monksdream Monksdream 1 month ago
Gnpx new 52/week low

👍️0
laraz5 laraz5 1 month ago
The entire BOD CEO and anyone associated with these possible pyramid schemes to raise money off the thought of Cancer need jail?

Ryan M confer might need to be in prison?


Genprex CEO possibly knows exactly the type of diluted pyramid scheme it is running?


Prison could have been a better fit for Varner but who I am I to question the lords work?


IMO
👍️0
TheFinalCD TheFinalCD 1 month ago
pop & drop!
gap & trap?

Cash Position

The company has -0.1 months of cash left based on quarterly cash burn of -$5.55M and estimated current cash of $-0.2M.

https://dilutiontracker.com/app/search/GNPX?a=dbb88c

https://finviz.com/quote.ashx?t=GNPX&ty=c&ta=1&p=d
👍️0
Awl416 Awl416 1 month ago
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
👍️0
laraz5 laraz5 2 months ago
Just another pyramid scheme involving a major medical corporation?

Arr they getting the kickbacks?

Is it OK to steal under a cancer premise?

MD Anderson owes people an explanation?

IMO
👍️0
Monksdream Monksdream 2 months ago
GNPX new 52 week low
👍️0
laraz5 laraz5 2 months ago
Michael Redmond might have set GNPX up to steal from Investors but the rest of this crew might have gone with it?

Send them all to prison theft is theft and this is on a massive scale if it turns out to be true?

IMO
👍️0
Monksdream Monksdream 2 months ago
GNPX new 52 week low
👍️0
laraz5 laraz5 2 months ago
Of course it is under 2 they are selling shares raising money?

I do not believe they even have an intention of a viable product?

Just a share selling machine of theft to me?

IMO
👍️0
Monksdream Monksdream 2 months ago
GNPX under $2
👍️0
laraz5 laraz5 2 months ago
Money laundering scam?


IMO
👍️0
Monksdream Monksdream 3 months ago
GNPX under $2
👍️0
laraz5 laraz5 4 months ago
**Complete Fraud** GNPX being used to raise money from epic amounts if pure dilution and promotion?

Bogus PRs, reverse splits, rinse and repeat and some of the worst dilution even seen?

A pyramid scheme of pure theft?

Genprex?

Officers should be in jail?


Every single one of them?


IMO
👍️0
jedijazz jedijazz 4 months ago
$GNPX $2.92 -(Nasdaq) New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms :NASDAQ: GNPX - EIN Presswire https://einnews.com/article/711037589/new-company-officers-appointed-after-promising-preclinical-data-on-gene-therapy-for-anti-tumor-mechanisms-nasdaq-gnpx via
@ein_news
$NRXP
👍️ 1 💯 1 😍 1
jedijazz jedijazz 4 months ago
$GNPX $3.30 +6.11% ---UPDATE
President, CEO and CFO, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes:
2024 BIO International Convention.
Date: Monday, June 3, 2024
Time: 2:00 pm PT
Venue: San Diego Convention Center -TheaterOne
👍️0
jedijazz jedijazz 4 months ago
$GNPX Genprex to Present at the 2024 BIO International Convention - "Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes" https://prn.to/3RdiwFv
👍️0
laraz5 laraz5 4 months ago
New O/S 2,098,698

It's about to get ugly?


IMO
👍️0
glenn1919 glenn1919 4 months ago
GNPX........................................https://stockcharts.com/h-sc/ui?s=GNPX&p=W&b=5&g=0&id=p86431144783
👍️0
jedijazz jedijazz 4 months ago
$GNPX Now $3.60 +48.76% Today HOD $3.96 #Bullish Exposure growing. Genprex to Present at the 2024 BIO International Convention
via PR Newswire, Thu, May 30, 2024

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes

https://www.prnewswire.com/news-releases/genprex-to-present-at-the-2024-bio-international-convention-302159043.html
👍️ 1 💪 1 😍 1
jedijazz jedijazz 4 months ago
$GNPX $2.72 +13.64% #Nasdaq Genprex Inc - 2024 BIO International Convention
https://finance.yahoo.com/news/genprex-present-2024-bio-international-123100674.html?soc_src=strm&soc_trk=tw via @YahooFinance
👍️0
jedijazz jedijazz 4 months ago
News: Genprex to Present at the 2024 BIO International Convention
PR Newswire
Thu, May 30, 2024, 8:31 AM EDT

In this article: $GNPX

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes

AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.

Event: 2024 BIO International Convention
Conference Dates: June 3-6, 2024
Presentation Date: Monday, June 3, 2024
Presentation Time: 2:00 p.m. PT
Venue: San Diego Convention Center in Theater 1
Presenter: Ryan Confer, Genprex's President, Chief Executive Officer and Chief Financial Officer

Mr. Confer will deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for in-person one-on-one meetings with participating attendees through the conference platform.

For those interested in meeting Genprex management during the conference, please request a meeting through the conference portal or reach out to Investor Relations at investors@genprex.com.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-the-2024-bio-international-convention-302159043.html

SOURCE Genprex, Inc.
👍️0

Your Recent History

Delayed Upgrade Clock